[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351525-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351525-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","kim-1-as-a-biomarker-in-genitourinary-neoplasms","KIM-1 as a Biomarker in Genitourinary Neoplasms","","Kidney Injury Molecule-1 (KIM-1), a type I transmembrane glycoprotein, is emerging as a promising biomarker in genitourinary malignancies. Initially linked to renal tubular injury, it is now studied across neoplasms, especially renal cell carcinoma, where expression associates with tumor grade, stage, and prognosis. Evidence supports non-invasive diagnostic potential via urinary and plasma/serum measurements as an adjunct to imaging and pathology. The review summarizes KIM-1 biology, expression patterns, and clinical implications in detection, prognosis, and treatment monitoring, while addressing limitations and future directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/kim-1-as-a-biomarker-in-genitourinary-neoplasms/351525/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/kim-1-as-a-biomarker-in-genitourinary-neoplasms/351525.png","ImageObject",300,407,{"name":42,"@type":43},"วิน","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is KIM-1 and why is it considered a biomarker in genitourinary cancers?","Question",{"text":63,"@type":64},"KIM-1 is a type I transmembrane glycoprotein. It was first described in renal tubular injury but is also studied for expression in genitourinary malignancies, where it may help with diagnosis, prognosis, and treatment monitoring.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How can KIM-1 be measured for clinical use?",{"text":68,"@type":64},"KIM-1 can be assessed using urinary and plasma/serum studies, providing a non-invasive approach. It may complement imaging and pathology-based evaluation.",{"name":70,"@type":61,"acceptedAnswer":71},"What limitations may affect KIM-1’s clinical specificity and implementation?",{"text":72,"@type":64},"Limitations include reduced cancer specificity in patients with chronic kidney disease and differences between laboratory assays. Prospective validation is needed before routine clinical use.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351525,1790244887,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Review  \nKIM-1 as a Biomarker in Genitourinary Neoplasms  \nChristos Veros 1,* and Aristotelis Bamias 2  \nAcademic Editor: Ke Chen  \nReceived: 15 February 2026  \nRevised: 7 April 2026  \nAccepted: 9 April 2026  \nPublished: 16 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece  \n2 Attikon University Hospital, 12462 Athens, Greece; [abamias@med.uoa.gr](abamias@med.uoa.gr)  \n* Correspondence: [cveros@med.uoa.gr](cveros@med.uoa.gr)  \nSimple Summary  \nUrological cancers include renal cancer, bladder cancer, prostate cancer, penile cancer and testicular germ cell tumors. The majority of patients occasionally face significant uncertainty during the course of their disease, regarding recurrence risk and treatment benefit.. Kidney injury molecule-1 (KIM-1) is a protein that can be possibly used as abiomarker to stratify patients in prognostic categories and offer valuable information about treatment response. It can be measured in urine, blood and tumor specimens. While it was first studied as a biomarker indicative of kidney injury, it is also overexpressed in renal cancer and more rarely in other tumors of the genitourinary system. This review focuses on KIM-1 function, detection and potential clinical utility, reflecting its usefulness in detecting urological cancers, estimating recurrence risk after surgery and potentially guiding adjuvant immunotherapy. We also discuss limitations such as reduced cancer specificity in patients with chronic kidney disease, differences between laboratory assaysand the need for prospective validation before routine clinical use.  \nAbstract  \nKidney Injury Molecule-1 (KIM-1), a type I transmembrane glycoprotein, is emerging as a promising biomarker in the landscape of genitourinary malignancies. Initially it was described for its role in renal tubular injury, but it is currently being studied for its expression in various neoplasms, particularly renal cell carcinoma, where it correlates with tumor grade, stage and prognosis. Recent studies have demonstrated its potential usefulness as a non-invasive diagnostic tool through urinary and plasma/serum studies, offering a valuable adjunct to imaging and pathology studies. KIM-1 may also play a role in urothelial cancer, although its specificity and relevance in this context are not clearly established yet. The following review presents our current knowledge on the biology of KIM-1, its expression patterns across various genitourinary tumors and its clinical implications in early detection, prognosis and treatment monitoring. We also explore the limitations and future directions regarding the integration of KIM-1 into precision oncology approaches.  \nKeywords: renal cell carcinoma; kidney injury molecule-1; KIM-1; urine biomarkers; blood biomarkers; adjuvant immunotherapy; minimal residual disease; genitourinary cancers  \n1. Introduction  \nGenitourinary cancers are biologically diverse and clinically heterogeneous malignancies. They include renal cell carcinoma (RCC), urothelial carcinoma of the bladder and upper urinary tract, prostate adenocarcinoma, penile cancer, testicular cancer and other  \nrarer entities. Among the aforementioned neoplasms, RCC is notable both for its incidence and for the challenges it conveys regarding diagnosis and postoperative surveillance. Cross-sectional imaging has increased the detection of renal incidentalomas. However, while some surgically removed renal masses are benign, many small RCCs are known to behave indolently [1] . On the other hand, a subset of patients with presumably localized RCC relapse after nephrectomy, highlighting the yet unmet need for new biomarkers that improve our ability to help individualize the recurrence risk beyond clinical and pathologic paramete","cbCaismQJlmDO2hv","https://ap.wps.com/l/cbCaismQJlmDO2hv","pdf",351304,12,"English","# Introduction\n## Renal cell carcinoma and unmet biomarker needs\n## Evolution of treatment strategies\n# Urothelial carcinoma management and emerging therapies\n## Intravesical, perioperative, and bladder-sparing approaches\n## Metastatic disease: ICIs, antibody–drug conjugates, and targeted therapy","[{\"question\":\"What is KIM-1 and why is it considered a biomarker in genitourinary cancers?\",\"answer\":\"KIM-1 is a type I transmembrane glycoprotein. It was first described in renal tubular injury but is also studied for expression in genitourinary malignancies, where it may help with diagnosis, prognosis, and treatment monitoring.\"},{\"question\":\"How can KIM-1 be measured for clinical use?\",\"answer\":\"KIM-1 can be assessed using urinary and plasma/serum studies, providing a non-invasive approach. It may complement imaging and pathology-based evaluation.\"},{\"question\":\"What limitations may affect KIM-1’s clinical specificity and implementation?\",\"answer\":\"Limitations include reduced cancer specificity in patients with chronic kidney disease and differences between laboratory assays. Prospective validation is needed before routine clinical use.\"}]","KIM-1 as a Biomarker in Genitourinary Neoplasms | PDF",1790094594,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d84e4932e57a57d90a0d5355ee07d111.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23bd83f62ca1bbff32a554b3466c438e.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b4270237ee6586ae98df4ac45caf10d.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18a3a06571bc5c8ece70f5094406f16a.webp",980,1385]